Receptors, Chimeric Antigen
VIDEO: CAR T-cells show quicker transduction time in multiple myeloma
In this video, Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope Cancer Center, discusses the progress in multiple myeloma highlighted at ASCO Annual Meeting.
FDA acts on CAR T-cell therapy, other top stories in hematology/oncology
The FDA recently granted its regenerative medicine advanced therapy designation to a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma — an indication that the therapy, called CT053, can address an unmet medical need for patients with the disease.
Top stories in hematology/oncology: USPSTF upholds recommendation against pancreatic cancer screening, cancer screening rates ‘unexpectedly high’ among oldest old
Among the top stories in hematology/oncology last week were the U.S. Preventive Services Task Force upholding its recommendation against pancreatic cancer screening for asymptomatic adults with no family history of the disease and a report that found individuals aged 85 years and older underwent cancer screening at “unexpectedly high” rates even though it is generally not recommended for this age group.
Patient access to new cancer treatments — an uncertain and fragile process
As Tom Brokaw eloquently stated, uncertainty is at the heart of the cancer experience for our patients.